43 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
10 Jul 15
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
12:00am
each other in the event that either Party has reason to believe that the recall of the Product, EGP-437 or the EyeGate® II Delivery System may … ”) of Product, EGP-437 or the EyeGate® II Delivery System including the necessity of declaring the Recall, the manner in which the Recall should
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Dec 22
Prospectus supplement
4:48pm
-terminating with a 2 sec shock) or unpaired stimuli (the same light and shock stimuli interleaved rather than overlapping). On day 2 (recall day … ), the authors presented the light stimulus alone. Sample recall trial movement traces of individual sham-injected rd1 mice (left, black), DENAQ-injected
424B1
KPRX
Kiora Pharmaceuticals Inc
22 Jul 22
Prospectus with pricing info
6:00pm
, each co-terminating with a 2 sec shock) or unpaired stimuli (the same light and shock stimuli interleaved rather than overlapping). On day 2 (recall day … ), the authors presented the light stimulus alone. Sample recall trial movement traces of individual sham-injected rd1 mice (left, black), DENAQ
8-K
EX-10.1
js59cphx1xkrka5 l75
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
r6ne4yf903t 7hx9pk
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
EX-10.1
gelrn8 i7
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
w9atn 07lg
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am